Cable Network Television Channel Broadcasts Remarks Pronouncing the Safety and Efficacy of Swiss Medica’s 024 Essential Oil Pain Reliever

TORONTO -- February 22, 2005 -- Swiss Medica Inc. (OTCBB:SWME) - On February 17th, Swiss Medica President, Grant Johnson, and the Company’s Medical Spokesman, Dr. Allan N. Fields, presented their commentaries about the efficacy of the O24 Essential Oil Pain Neutralizer as a safe alternative to Cox-2 inhibitors and NSAIDs (non-steroidal anti-inflammatory drugs) before the U.S. Food and Drug Administration advisory panels: the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The purpose of this health panel was to issue recommendations about the cardiovascular safety of Cox-2 inhibitor medicines and the non-steroidal anti-inflammatory drugs.

The entirety of the presentations made by Mr. Johnson’s and Dr. Fields were broadcast live by the C-SPAN cable network television channel, and aired again on February 20th.

Both Swiss Medica spokesmen recommended the O24 Essential Oil Pain Neutralizer be considered as a serious, but selective, replacement for those currently prescribed Cox-2, or for those self-prescribing over the counter, anti-inflammatory medicines.

Dr. Allan Fields announced to the joint FDA advisory panel, “I personally am asked on a daily basis what can patients do or take to control pain. I have been advising my patients to minimize the use of oral prescription and OTC medications and instead, to use O24 which, due to its purity, does no harm to the human body. This has provided pain relief that often lasts 6-8 hours. The patients have been using less of the aforementioned drugs and saving money in the process. No serious adverse effects, such as GI bleed, hypertension or cardiovascular problems have ever been reported. There is no interference with other medications that are necessary to maintain the patient’s health.”

Mr. Johnson explained to the FDA advisory panel, “ At Swiss Medica, we have compiled scientific evidence that powerful topical pain relievers, such as our O24 topical pain reliever, may be nearly as effective as many oral medications. But without the side effects such as bleeding ulcers, higher blood pressure or increased risk to the heart. These claims are supported by three European medical studies, one American-based open trial, and a recently completed Canadian randomized, double-blind clinical study over an extended period of time.”

The 50-member FDA advisory panel was presented with an information package, which included one-ounce O24 bottles and towelettes, the O24 information booklet entitled “Natural Relief for Musculoskeletal Pain,” and summaries of medical studies, including an unpublished U.S. open trial of O24 compared to other pain relievers.

Swiss Medica’s public relations team broadly disseminated complimentary O24 towelettes and the O24 information guide to the majority of those attending the FDA hearings, including numerous clinicians, university-affiliated physicians and researchers, FDA executive and staff, and the media, during the three-day hearings.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com

Swiss Medica’s flagship product, the O24(TM) Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24(TM) pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24(TM) is widely available throughout Canada in leading pharmacies and natural food stores. It is currently available in Happy Harry’s Discount Drugstores in the United States, or by visiting www.O24zone.com, for ordering details and store locators.

Forward-looking statements in this news release are made pursuant to the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica Inc. (OTC Bulletin Board:SWME)

Contact Information

Sky Wallen

Press Contact

Blue Skye PR, Inc.

Contact via E-mail